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Abstract 
We found that vitamin D 3 up-regulates the expression of cytidine deaminase (CDD) gene in some human solid tumor cell lines as well 
as the monocytic leukemia cell lines. Two kinds of full length CDD cDNA were identified from human placenta: one has glutamine and 
the other one has lysine at codon 27. The expression was tested in various normal tissues and the cancer cell lines. Northern blot analysis 
demonstrated high levels of CDD mRNA in leukocytes and moderate l vels in liver, kidney, placenta, spleen and lung. Expression of 
CDD in 20 human cancer cell lines was highly variable and not related to its expression in normal tissues. Treatment of the cell lines with 
1 t~,25-dihydroxyvitamin D 3 resulted in up-regulation of CDD expression i  some lines but not others. Three of five gastric carcinoma 
cell lines and five of eight colorectal cancer lines had increased levels of CDD mRNA following 24 h treatment with vitamin D 3. 
Increased mRNA was detected in gastric ancer MKN 45 cells after 3 h of treatment with vitamin D 3 and increased enzyme activity was 
measured after 24 to 48 h. But no combined effect of calcitriol with 9-cis retinoic acid was found. Our results demonstrate that CDD can 
be up-regulated by vitamin D 3 in some solid tumor cell lines. 
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1. Introduction 
The enzyme cytidine deaminase (CDD; EC 3.5.4.5), 
which catalyzes the deamination of cytidine or deoxycyti- 
dine to uridine or deoxyuridine, respectively, plays an 
important role in regulating the activity of several anti- 
cancer drugs [1,2]. A new class of fluoropyrimidine pro- 
drugs has been designed that requires deamination by 
CDD in order to become activated. One example that has 
been studied in animal models is galocitabine (Na- t r i  - 
methoxybenzoyl-5'-deoxy-5-fluorocytidine [3,4]). This 
compound is rapidly absorbed through the intestinal tract 
and cleaved in liver by acylamidase to give 5'-deoxy-5-flu- 
orocytidine (5'-dFCrd). This, in turn, is the substrate for 
CDD and is cleaved to 5'-deoxy-5-fluorouridine (5'-dFUrd, 
doxifluridine). Doxifluridine is further converted, primarily 
Abbreviations: CDD, cytidine deaminase; 5'-dFCrd, 5'-deoxy-5-fluo- 
rocytidine; 5'-dFUrd; 5'-deoxy-5-fluorouridine; GST, glutathione S-trans- 
ferase; VDR, vitamin D 3 receptor; RXR, 9-cis retinoic acid receptor. 
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in tumor cells, to 5-fluorouracil by pyrimidine nucleoside 
phosphorylase [5,6]. 
A group identified an incomplete cDNA for CDD by 
differential hybridization of a library prepared from U937 
monocytic leukemia cells that had been induced to differ- 
entiate in vitro by vitamin D 3 (calcitriol) and interferon 3' 
[7,8]. Differentiated U937 cells have much higher levels of 
CDD activity than do undifferentiated cells. They further 
showed that the gene was up-regulated by vitamin D 3 in 
U937 and another myeloid leukemia line, HL60. The full 
length cDNA for CDD was identified from a human liver 
cDNA library by another group [9]. The CDD sequence 
from the human liver was identical to that from U937 
except for one amino acid at codon 27 :U937 (CAG: 
glutamine) and liver (AAG:  lysine). 
We have identified the two types of cDNAs for CDD 
from a human placenta cDNA library. These cDNAs were 
expressed in COS-7 cells and the two types of enzymes 
were verified to have the same activity of CDD. We have 
examined expression of CDD mRNA in human cancer cell 
lines derived from gastric, colorectal, breast, bladder, hep- 
atoma, and lung carcinomas. In addition, we have exam- 
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ined the effect of calcitriol on expression of CDD in some 
of these lines to determine if up-regulation is a general 
effect of this agent in cancer cells, or is a cell line specific 
effect, possibly related to differentiation. We found that 
expression is up-regulated in some, but not all lines. In one 
line, the gastric carcinoma cell line MKN 45, we also 
examined the combined effect of calcitriol with the retinoid 
9-cis retinoic acid, because these agents have been demon- 
strated to have synergistic activity for inducing differentia- 
tion of U937 cells [10]. 
2. Materials and methods 
2.1. cDNA cloning 
Based on the published partial sequence of human CDD 
[5], primers were synthesized toprepare a 241 base cDNA 
probe by PCR amplification. The PCR primers were CDD 1 
(sense: 5'-GCTGCCCTCCTCCTTG-3') and CDD2 (anti- 
sense: 5'-GGGGCGGCGGTGTTCTA-3'). A total of 40 
cycles of amplification with 40 s at 94°C, 2 min at 50°C 
and 1 min 20 s at 72°C were performed. The PCR product 
was sequenced to ascertain that it was identical to the 
reported sequence. Twenty 150-mm plates, containing 9 X 
105 plaques of human placental A phage from a cDNA 
library (Clontech, Palo Alto, CA), were lifted onto nylon 
membranes (Colony/Plaque Screen, DuPont, Boston, MA) 
and pre-hybridized in 6 X SSC (1 X SSC: 0.02% Ficoll, 
0.02% polyvinylpyrrolidone, 0.02% serum albumin), 0.5% 
SDS, 50% formamide and 100 /.~g/ml of salmon sperm 
DNA at 42°C. Membranes were washed twice for 30 min 
at room temperature in a solution containing 2 X SSC and 
0.1% SDS. The membranes were exposed overnight o 
Kodak XAR film at -70°C. 
Positive plaques were further purified to homogeneity 
using the same procedure. A clone of 900 bases was 
isolated, and sequencing demonstrated that it consisted of 
the full length coding region as well as 5' and 3' untrans- 
lated regions, including the poly(A) tail. 
2.2. Expression of recombinant protein in E. coli 
2.3. Cytidine deaminase assay 
Cytidine deaminase activity was assayed by measuring 
the amount of 5'-dFUrd that was produced from 5'-dFCrd. 
Aliquots of the cell lysates or purified protein were ad- 
justed to give 100 /zl of reaction mixture that contained 
183 mM potassium phosphate buffer (pH 7.4) and 2 mM 
5'-dFCrd. The samples were incubated for 60 min at 37°C, 
and the reaction was terminated by adding 300 /zl of 
methanol and cooling for 10 min on ice. The precipitate 
was removed by centrifugation at 3000 × g for 10 min, 
and 100 /zl aliquots of supernatant were supplemented 
with 0.01 mM 5-chlorouracil as an internal standard. The 
samples were then applied to an HPLC column (6 X 200 
mm, ERC-ODS-1171, ERMA Cr.). The column was eluted 
with 50 mM sodium phosphate buffer (pH 6.8) containing 
5 mM 1-decanesulfonic a id-methanol (85:15, v /v)  at a 
flow rate of 1 ml/min. Protein concentration was deter- 
mined by the Lowry method [11]. 
2.4. Cell culture 
The gastric cancer cell lines MKN 1, MKN 28 and 
MKN 45 were obtained from the Immunobiological Labo- 
ratories (Fujioka, Japan). The colorectal cell line CXF 280 
was obtained from Prof. H.H. Fiebig (University of 
Freiburg, Germany). All other cell lines were purchased 
from ATCC (Bethesda, MD). These include a normal 
fibroblast cell line (WI 38), 2 gastric cancer cell lines 
(AGS and KATO III), a myeloid leukemia line (HL 60), 7 
colon cancer cell lines (WiDr, HCT116, Lo Vo, DLD-1, 
Colo 201, Colo 205 and Colo 320DM), 3 breast cancer cell 
lines (MDA-MB-231, ZR-75-1, and MCF7), a bladder 
cancer line (T24), a lung adenocarcinoma line (A549) and 
hepatoblastoma cell line (Hep G2). The cells were plated 
in RPMI 1640 medium containing 5% fetal calf serum and 
incubated in a fully humidified atmosphere containing 5% 
CO 2. After 48 h of incubation, calcitriol was added at a 
concentration f 200 nM. The cultures were incubated for 
24 h before RNA was extracted. In one experiment, MKN 
45 cells were treated with 200 nM of calcitriol, 200 nM of 
9-cis retinoic acid or both for various periods of time. 
The cloned 900 bp cDNA was expressed as a fusion 
protein by ligating the fragment to the glutathione S-trans- 
ferase (GST) gene in pGEX2T (Pharmacia, Uppsala). This 
plasmid, pGEX2T-CDD, was transfected into E. coli 
DH5a (Clontech). The transformant was cultured at 25°C 
for 18 h, and expression of the recombinant GST-CDD 
fusion protein was induced by treatment with 0.1 mM 
IPTG. The GST-CDD protein was extracted from the 
sonicated cells, suspended in PBS and isolated by glu- 
tathione Sepharose 4B (Pharmacia) column chromatog- 
raphy. The purified protein was identified by SDS 10-20% 
(w/v)  gradient polyacrylamide g l electrophoresis (ATTO, 
Tokyo). 
2.5. Northern blotting 
The expression of CDD in various tissues and tumor 
cell lines was examined by Northern blot analysis as 
described elsewhere [12]. Total RNA was isolated from 
each tumor cell line by extraction with guanidine thio- 
cyanate. 20 /~g of these RNAs were loaded onto 1% 
agarose gels containing 6% formaldehyde and separated by 
electrophoresis. The RNAs were then transferred to nylon 
membranes (Hybond-N; Amersham, Aylesbury). For de- 
termining the distribution of CDD in normal tissues, we 
used RNA blot membranes from Clontech. The mem- 
branes were hybridized with a probe prepared from the 
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900 bp CDD cDNA by random primer labeling with 
[a-32p]dCTP. The filters were re-hybridized with 32p_ 
labeled /3-actin cDNA as a control for the amount of RNA 
loaded. Hybridization and wash conditions were the same 
as described above. The bands appearing on the film were 
measured by a densitometer (BAS 1000, Fujifilm Co., 
Tokyo). 
3. Results 
3.1. Cloning and expression of human CDD 
(kb) 
9.5- 
7.5- 
4.4- 
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1.35- 
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To study expression of CDD in human tumors, we 
cloned the human CDD cDNA from a human placenta 
cDNA library. Two types of cDNA including a 438 bp 
protein coding region were identified. There is one base 
difference at codon 27 between these clones: (CAG: glu- 
tamine) and (AAG: lysine). The sequence of the clone 
containing CAG at codon 27 was identical to that from 
U937, and the sequence of the other clone containing AAG 
there is identical to that from a human liver. The sequence 
predicts a protein product of 146 amino acids with a 
molecular mass of 16 184 Da. 
To verify that the recombinant CDD protein had enzy- 
matic activity, we expressed it as a GST-CDD fusion 
protein in E. coli. The relative activity of the recombinant 
GST-CDD in the bacterial ysate was 1325 nmol of 5'- 
dFCrd/mg protein/min converted to 5'-dFUrd. This was 
62 times higher than the relative activity of CDD in lysate 
from non-transformed E. coli (21.5 nmol/mg protein per 
min). The protein was affinity purified on a glutathione 
column and was identified as a single band running at 
approximately 42 kDa after SDS polyacrylamide g l elec- 
trophoresis (Fig. 1). This is compatible with a combined 
molecular weight of about 27 kDa for GST and 16 kDa for 
CDD. 
GST- 
CDD M (kDa) 
-97.4 
-66.3 
-42.4 
-30 
-20.1 
-14.4 
Fig. 1. Identification of the recombinant GST-CDD fusion protein. The 
protein containing lysate from E. coli was purified by glutathione 
Sepharose 4B column chromatography and then analyzed by SDS poly- 
acrylamide gel electrophoresis. The gel was stained with Coomassie 
brilliant blue staining. 
Fig. 2. Northern blot analysis of CDD mRNA in various tissues. Lanes of 
the nylon membranes contained 2 /xg of poly(A) + RNA from different 
human tissues (Clontech). The blots were hybridized with 32P-labeled 
CDD cDNA. The lanes contained the RNAs from various tissues as 
follows: 1, spleen; 2, thymus; 3, prostate; 4, testis; 5, ovary; 6, small 
intestine; 7, colon; 8, peripheral blood leukocytes; 9, heart; 10, brain; 11, 
placenta; 12, lung; 13, liver; 14, skeletal muscle; 15, kidney; 16, pan- 
creas. 
3.2. Identification of CDD mRNA in normal tissues 
The results of Northern blot analysis showed that the 
total length of CDD mRNA in all normal and tumor 
tissues examined is about 900 bp (Figs. 2 and 3), similar in 
length to our cDNA clone. In normal human tissues (Fig. 
2), CDD mRNA was most highly expressed in peripheral 
blood leukocytes as expected from the fact that mature 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 
VD3 - -+- -+- -+- -+- -+ - -+- -+- -+- -+- -4 -  -- + 
13-actin '~  
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VD3 ---t" --"1- - - "~- - ' t "  - -+- - " l ' - -q - - -+- -+- -+ 
G D D - ~  
1 3 - a c t i n ~  
Fig. 3. Effect of calcitriol on expression of CDD mRNA in human cell 
lines. The cells were incubated with 1130 nM calcitriol for 24 h before 
RNA was isolated. Total RNA (20 /xg) was loaded in each lane. The cell 
lines include: WI 38, normal fibroblast (lanes 1 and 2); WiDr, colon 
carcinoma (3 and 4); HCT116, colon carcinoma (5 and 6); MKN 45, 
gastric cancer (7 and 8); T24, bladder cancer (9 and 10); A549, lung 
adenocarcinoma (11 and 12); MCFT, breast cancer (13 and 14), ZR-75-1, 
breast cancer (15 and 16); Hep G2, hepatoblastoma (17 and 18); HL 60, 
myeloid leukemia (19 and 20); MDA-MB-231, breast cancer (21 and 22); 
MKN 1, gastric ancer (23 and 24); MKN 28, gastric ancer (25 and 26); 
AGS, gastric cancer (27 and 28); KATO HI, gastric cancer (29 and 30); 
Colo 201, colorectal cancer (31 and 32); Colo 205, colorectal cancer (33 
and 34); Colo 320DM, colorectal cancer (35 and 36); CXF 280, colorec- 
tal cancer (37 and 38); Lo Vo, colorectal cancer (39 and 40); DLD-1, 
colorectal cancer (41 and 42). The RNA in odd numbered lanes was from 
untreated cells; that in even numbered lanes was from calcitriol treated 
cells. 
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granulocytes [2] and macrophages [8] have high levels of 
enzyme activity. There was moderately high expression of 
CDD mRNA in liver, kidney, placenta, spleen and lung. 
Expression was lowest in brain. 
3.3. Expression of  the CDD gene in tumor cell lines and 
regulation by calcitriol 
Fig. 3 shows the Northern analysis results for CDD 
mRNA expression in 20 human tumor cell lines and one 
normal human fibroblast cell line (WI 38). It is clear that 
expression varies highly from line to line. There appears to 
be no relationship between tissue of origin and expression. 
For instance, the colon carcinoma lines WiDr, DLD-1, Lo 
Vo and Colo 320DM had very low basal levels of expres- 
sion, whereas expression in HCT116, Colo 201, Colo 205 
and CXF 280 was much greater than that seen in normal 
colon (Fig. 2). The hepatoblastoma line Hep G2, on the 
other hand, expressed lower levels than normal liver. The 
gastric carcinoma lines MKN 1 and MKN 45 highly 
expressed CDD. Another gastric carcinoma line, MKN 28, 
expressed moderate levels. Barely detectable levels of 
CDD mRNA were expressed in the gastric lines AGS and 
KATO III. The lung adenocarcinoma line A549 contained 
very high levels of CDD mRNA. The basal levels of CDD 
mRNA in the breast cancer lines MDA-MB-231, MCF7 
and ZR-75-1 were very low. 
The effect of 24 h treatment with calcitriol on expres- 
sion of CDD in the cancer cell lines is also shown in Fig. 3 
and Table 1. As previously reported [8], CDD mRNA was 
increased in HL 60 myeloid leukemia cells by calcitriol. 
Similar up-regulation was also seen in one of the three 
breast cancer cell lines tested (MDA-MB-231), in five of 
eight colorectal carcinoma cell lines (WiDr, Colo 201, 
Colo 205, CXF 280 and DLD-1), in three of five gastric 
carcinoma lines (MKN 45, MKN 1 and MKN 28), as well 
as the lung adenocarcinoma line (A549). The increased 
expression of CDD mRNA in HL 60, MDA-MB-231, Colo 
201, CXF 280, DLD-I,  MKN 45, MKN 1 and MKN 28 
was verified by measuring the bands on the X-ray film 
with a densitometer (Table 1). Moreover the increases in 
(a) (b) (c) 
o 3 8 24 483 8 24 48 3 8 24 48 
28s- 
18S- 
CDD 
J3-actin 
Fig. 4. Effect of calcitriol and 9-cis retinoic acid on CDD expression i
MKN 45 cells at various times. Cells were treated with (a) calcitriol, (b) 
9-cis retinoic acid, or (c) both for 0, 3, 8, 24 and 48 h. Total RNA (20 
/xg) was loaded in each lane. 
mRNA levels were verified to reflect in protein expression 
as determined by enzyme in these lines (Table l). 
The time course of expression of CDD mRNA in MKN 
45 cells treated with calcitriol was examined (Fig. 4a). The 
amount of mRNA was visibly increased after 3 h of 
treatment and continued increasing through 48 h of treat- 
ment. The protein expression as determined by enzyme 
activity increased from a baseline level of 1.7 nmol /mg 
protein per min to 2.0 nmol /mg protein per rain at 8 h, 2.7 
nmol /mg protein per min at 24 h and 4.1 nmol /mg 
protein per rain at 48 h. 
The effect of 9-cis retinoic acid on CDD mRNA ex- 
pression was also examined in the experiment shown in 
Fig. 4b. Treatment of ceils with 9-cis retinoic acid de- 
creased the expression of CDD with a time course similar 
to that seen for the up-regulation by calcitriol. In the 
combination study (Fig. 4c), 9-cis retinoic acid appeared to 
abolish the stimulatory effect of calcitriol. 
4. Discussion 
We have cloned human CDD cDNA so that we could 
examine expression of this enzyme in human tumor cells, 
where its presence can lead to inactivation of some clini- 
Table 1 
Induction of CDD protein and mRNA in various tumor cell lines by VD3 
Cell CDD activity (nmol/mg protein per min) 
control + VD3 
CDD activity 
(fold) + VD3/control 
CDD mRNA level * 
(fold) + VD3/control 
HL 60 0.040 + 0.002 0.26 + 0.01 6.6 3.4 
MDA-MB-231 8.3 ::1:0.2 11 + 1.4 1.3 1.1 
MKN 7.7 ±0.06 11 +0.1 1.5 1.3 
MKN28 1.1 ±0.01 1.3 ±0.01 1.2 2.1 
MKN45 5.1 ±0.3 6.2 ±0.2 1.2 1.9 
Coin 201 3.7 ± 0.2 4.5 + 0.2 1.2 1.5 
CXF 280 3.9 ± 0.4 4.4 ± 0.3 1.1 1.2 
DLD-1 0.24 ± 0.01 0.42 ± 0.06 1.8 1.2 
* The level of CDD mRNA was verified by measuring the bands on the X-ray film with a densitometer. 
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cally important anticancer drugs or to increased activation 
of newer fluoropyrimidine pro-drugs. We identified several 
clones coding the sequence of CDD cDNA from human 
placenta, which are identical to the coding sequence re- 
ported for the U937 cell gene [8] or the human liver gene 
[9]. There is one base difference between them, which 
causes one amino acid difference, but the two have CDD 
activity. 
High levels of CDD mRNA are expressed in normal 
peripheral blood leukocytes and some tissues such as liver, 
kidney, and lung whereas most other tissues show only 
low levels of expression. Comparison of the expression 
levels in normal human tissues and tumor cell lines indi- 
cates that no clear relationship exists. Cytidine deaminase 
is highly over-expressed in four colorectal cancer cell lines 
compared to normal colon or the other four colorectal lines 
examined. Similarly, two gastric cell lines highly over-ex- 
press CDD, whereas moderate levels are present in one 
line and two lines had very low levels of expression. These 
results suggest hat tumor to tumor variation in expression 
of CDD may be quite large and could explain the relative 
lack of activity of azacitidine and cytarabine in many solid 
tumors. 
In human myelocytic leukemia lines, calcitriol induces 
differentiation and increased expression of CDD mRNA. 
To determine if this is specific for monocyte differentia- 
tion or is a more general feature of cell treated with 
vitamin D3, we examined the effect of calcitriol in a 
variety of human tumor cell lines. Proliferation of several 
breast cancer cell lines is known to be inhibited by cal- 
citriol in vitro. These lines include ZR-75-1 [13] and 
MCF7 [14,15]. However, CDD expression was not affected 
by calcitriol treatment either in ZR-75-1 or MCF7 cells, 
whereas it was in MDA-MB-231 cells, which are insensi- 
tive to vitamin D 3 treatment [13]. This indicates that 
sensitivity to vitamin D 3 of one of these parameters does 
not necessarily correlate with sensitivity in the other pa- 
rameter for any particular cell line. Other cell lines, includ- 
ing the majority of those derived from colorectal and 
gastric tumors did show up-regulation of CDD in response 
to calcitriol. However, it was not a universal phenomenon 
and some lines, particularly those with little or no basal 
expression, were not responsive to vitamin D 3. 
These results, demonstrating up-regulation of CDD in 
some solid tumor cell lines but not others, have several 
implications of relevance for treatment of cancer patients. 
Treatment with vitamin D 3 or its analogues could lead to 
decreased efficacy in patients given cytidine analogues like 
cytarabine or azacitidine. On the other hand, combination 
treatment with vitamin D 3 analogues could increase the 
efficacy of fluoropyrimidine pro-drugs like galocitabine or 
capecitabine in some tumors. In a preliminary experiment, 
incubation of MKN 45 cells with calcitriol appeared to 
increase their sensitivity to 5'-dFCrd without increasing 
their sensitivity to 5'-dFUrd, the product of the deamina- 
tion. 
Calcitriol binds to the vitamin D nuclear receptors 
(VDR) and the activated VDRs can form heterodimers 
with RXR, the nuclear receptors for 9-cis retinoic acid. 
The transactivating activity of VDR-RXR heterodimers i
considerably more efficient than that of either homodimer 
with some genes [16], but not others [17]. These het- 
erodimer activities may be reflected by synergistic interac- 
tions between vitamin D 3 and retinoids. Differentiation of 
U937 myeloid leukemia cells, when they are treated with 
both calcitriol and 9-cis retinoic acid, is greater than the 
additive effects of either agent alone [10]. Synergy be- 
tween vitamin D 3 and all-trans retinoic acid has been 
reported with breast cancer cells as well [18]. If the CDD 
gene is directly regulated by VDR, these results would 
indicate that VDR homodimer binding is important and 
RXR as a homodimer or heterodimer could be a repressor 
of transcription. However, it is not clear from our experi- 
ments whether the promoter of CDD is directly regulated 
by these hormone receptors or if these effects are sec- 
ondary, as suggested by the fact that they are cell line 
specific. Further study is necessary to clarify this mecha- 
nism. 
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